Literature DB >> 10049831

Smubp-2 represses the Epstein-Barr virus lytic switch promoter.

Q Zhang1, Y C Wang, E A Montalvo.   

Abstract

Smubp-2 is a novel transcription factor that was first identified through its interaction with the immunoglobulin Smu region (Mizuta et al., 1993) and has been cloned by virtue of its binding to two 12-O-tetradecanoylphorbol-13-acetate-responsive elements in the Epstein-Barr virus immediate-early BZLF1 promoter (Gulley et al., 1997). In this report, we examined the effect of Smubp-2 overexpression on BZLF1 prom oter activity. Overexpression of Smubp-2 in the B lymphocyte cell line BJAB caused repression of the BZLF1 gene promoter. A 14-bp region that partially overlaps with a 12-O-tetradecanoylphorbol-13-acetate-responsive element was required for maximal repression by Smubp-2, but some repression was also seen with a minimal promoter containing only the BZLF1 promoter TATA box and an initiation site. A 30-bp fragment containing the 14-bp region could transfer Smubp-2-mediated repression to heterologous promoters. Smubp-2 was found to associate with the basal transcription factor TATA binding protein (TBP) and to disrupt the formation of a stable TBP-TFIIA-DNA complex on the BZLF1 promoter TATA box and the adenovirus E1B promoter TATA box. Repression of the BZLF1 promoter by overexpressed Smubp-2 was rescued by overexpression of the basal factor TFIIA. These results suggest that complete repression of the BZLF1 promoter by Smubp-2 involves disruption of a functional TBP-TFIIA-TATA box complex and requires the -93 bp-to--79 bp region of the promoter. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049831     DOI: 10.1006/viro.1998.9588

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.

Authors:  R J Kraus; S J Mirocha; H M Stephany; J R Puchalski; J E Mertz
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Association of a single-nucleotide polymorphism in the immunoglobulin mu-binding protein 2 gene with immunoglobulin A nephropathy.

Authors:  Shigeru Ohtsubo; Aritoshi Iida; Kosaku Nitta; Toshihiro Tanaka; Ryo Yamada; Yozo Ohnishi; Shiro Maeda; Tatsuhiko Tsunoda; Takashi Takei; Wataru Obara; Fumihiro Akiyama; Kyoko Ito; Kazuho Honda; Keiko Uchida; Ken Tsuchiya; Wako Yumura; Takashi Ujiie; Yutaka Nagane; Satoru Miyano; Yasushi Suzuki; Ichiei Narita; Fumitake Gejyo; Tomoaki Fujioka; Hiroshi Nihei; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2004-12-14       Impact factor: 3.172

3.  Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent.

Authors:  Monir Shababi; Zhihua Feng; Eric Villalon; Christine M Sibigtroth; Erkan Y Osman; Madeline R Miller; Patricka A Williams-Simon; Abby Lombardi; Thalia H Sass; Arleigh K Atkinson; Michael L Garcia; Chien-Ping Ko; Christian L Lorson
Journal:  Mol Ther       Date:  2016-02-10       Impact factor: 11.454

4.  The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency.

Authors:  Xianming Yu; Patrick J McCarthy; Hui-Jun Lim; Tawin Iempridee; Richard J Kraus; Daniel A Gorlen; Janet E Mertz
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

5.  Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency.

Authors:  Takayuki Murata; Chieko Noda; Shinichi Saito; Daisuke Kawashima; Atsuko Sugimoto; Hiroki Isomura; Teru Kanda; Kazunari K Yokoyama; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2011-04-27       Impact factor: 5.157

6.  The Ighmbp2D564N mouse model is the first SMARD1 model to demonstrate respiratory defects.

Authors:  Caley E Smith; Monique A Lorson; Sara M Ricardez Hernandez; Zayd Al Rawi; Jiude Mao; Jose Marquez; Eric Villalón; Amy N Keilholz; Catherine L Smith; Mona O Garro-Kacher; Toni Morcos; Daniel J Davis; Elizabeth C Bryda; Nicole L Nichols; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2022-04-22       Impact factor: 5.121

7.  Validation of the Pathogenic Effect of IGHMBP2 Gene Mutations Based on Yeast S. cerevisiae Model.

Authors:  Weronika Rzepnikowska; Joanna Kaminska; Andrzej Kochański
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

8.  A Direct Comparison of IV and ICV Delivery Methods for Gene Replacement Therapy in a Mouse Model of SMARD1.

Authors:  Monir Shababi; Eric Villalón; Kevin A Kaifer; Vince DeMarco; Christian L Lorson
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-17       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.